Clinical dosimetry in the treatment of bone tumors: old and new agents
Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency (Sm-153-EDTMP and Sr-89-Cl-2) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries (Re-186-HEDP,